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Background

Results

• Patients with cancer and those undergoing chemotherapy are at risk of developing
bacterial infections due to myelosuppression. Patients undergoing the most
intensive chemotherapy regimens are at a higher risk for morbidity and mortality
due to profound neutropenia.
• Antibacterial prophylaxis is given to reduce the incidence of infection in those at

Outcomes

Levofloxacin Ciprofloxacin p-value

n (%)

n = 70

n = 115

Neutropenic
fever

50 (71.4%)

95 (82.6%)

antibacterial prophylactic medications at different time points, these were

0.056

29 (41.4%)

54 (47%)

0.496

• Starting March 1, 2016, our institution used ciprofloxacin for prophylaxis however

Fungal infection

8 (11.4%)

7 (6.1%)

0.216

recent literature supports using levofloxacin in certain high risk (HR) populations

C. difficile

6 (8.6%)

15 (13%)

0.261

ICU admission

11 (15.7%)

11 (9.6%)

0.249

due to greater efficacy in reducing neutropenic fever (NF) and bacteremia.
• Therefore, we switched to this April 1, 2019 and used this change in our standard
of care as an opportunity to evaluate instances of NF and bacteremia between the
two fluoroquinolones.
• Objective: To determine if there is a significant difference in the incidence of NF,

bacteremia, fungal infections, Clostridioides difficile infections, and intensive care
unit (ICU) admissions in patients with malignancies at HR for infection [defined as
acute myeloid leukemia (AML), relapsed acute lymphoblastic leukemia/ lymphoma
(ALL), infant ALL, Down Syndrome ALL, Burkitt lymphoma, and those who have
undergone autologous or allogenic hematopoietic stem cell transplant (HSCT)] in
those who have received levofloxacin compared to ciprofloxacin prophylaxis

separated into different encounters. Each relapse instance and transplant
period were also separated. This method brought the total number of

Bacteremia

highest risk.

• A total of 133 patients were included however as some patients received both

encounters to 115 for ciprofloxacin group and 70 for levofloxacin group.
• Median age was 6 years, 58% were male, and 62% were White
• Fluoroquinolone exposure time was similar for both groups (p=0.99)
• Of the 115 ciprofloxacin encounters, 95 (82.6%) had at least one episode of NF
while this was the case in 50 (71.4%) of the levofloxacin encounters. This
finding approached significance with p value = 0.056.
• The median number of neutropenic fever episodes, which took in to account
the length of exposure, was 1 for the ciprofloxacin group (IQR 1-2) and 1 for
the levofloxacin group (IQR 0-2), p = 0.052.
• Percentage of bacteremia episodes, fungal infections, C. difficile infections,
and admissions to ICU was not statistically significant between patients who
received ciprofloxacin compared to those who received levofloxacin.

Conclusion
• Levofloxacin as antibacterial prophylaxis is the standard of care at our

Methods

institution for patients at HR for infection.
• This is a retrospective chart review study of patients at HR for infection and who

• While difference in incidence and median number of NF did not reach

received bacterial prophylaxis with levofloxacin and/or ciprofloxacin from March 1,

statistical significance between the levofloxacin and ciprofloxacin groups, it did

2016 to June 30, 2020.

approach significance which is clinically noteworthy as this will result in less

• We reviewed charts individually and collected data including patient
demographics, details regarding antimicrobial prophylaxis and the incidence of NF,
bacteremia, fungal infections, C. difficile infections, and ICU admissions.
• Logistic regression models with repeated measures approach was performed for
the dichotomous outcomes.

If questions, please contact
cdargan@cmh.edu

hospitalizations and less cephalosporin exposure.

• Further analysis regarding incidence of alpha hemolytic strep bacteremia and
fluoroquinolone resistance as well as outcomes by diagnosis will be performed.
• Future studies with a larger patient population would be beneficial.

